Phase 2 N=33 A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects
Dental Caries
Primary: Safety of Multiple C16G2 Varnish Applications — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 68 Ga-PSMA for High Risk Prostate Cancer
Prostate Cancer · High Risk
Primary: Proportion of Patients With Lymph Node Involvement — 4; 28 Participants
Phase 2 N=41 Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Changes in mRNA Expression in Blood of STAT3, PPAR-ɣ, and STC-1 at T0 — 4.19; 7.58; 6.43; 11.32 delta Ct (amplification cycles) — p=0.22
Phase 2 N=28 Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Fibrolamellar Carcinoma · Fibrolamellar Liver Cancer
Primary: Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6) — 0; 0; 0; 9 Participants
N/A N=96 Study to Evaluate Bone and Gum Dimension Changes Around Dental Implants Placed in Different Positions in Bone.
Mouth, Edentulous
Primary: Change in Marginal Bone Level (MBL) — -0.14; -0.002; -0.20; -0.07 mm
Phase 2 N=27 Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants
Phase 1 N=14 Delineation of Sensorimotor Subtypes Underlying Residual Speech Errors
Speech Sound Disorder
Primary: Normalized F3-F2 Distance, an Acoustic Measure That Correlates With Perceptual Accuracy of /r/, Measured From /r/ Sounds Produced in Treatment Sessions. — 5.73; 6.27…
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Phase 2 N=74 Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Lymphoma, Non-Hodgkin · Lymphoma, Nonhodgkin · Lymphoma, B-Cell
Primary: Overall Response Rate (ORR) — 80.3 Percent of Participants — p=<.0001
Phase 4 N=90 Copper Intrauterine Device (IUD) Insertion at Cesarean Delivery
Intrauterine Device Expulsion
Primary: Number of Participants With Expulsion of IUD — 54; 0 Participants
Phase 2 N=112 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Neuroblastoma · Medulloblastoma
Primary: Number of Participants With Related Adverse Events as a Measure of Safety and Tolerability — 45 Participants
N/A N=5 Connect for Caregivers
Social Isolation · Loneliness
Primary: Perceived Autonomy — 21.2 score on a scale
Phase 3 N=32 Behavioral Mechanism of Energy Compensation With Exercise
Obesity · Weight Loss · Eating Behavior
Primary: Attentional Bias — 48.85 percentage of time fixated on food cues
Phase 3 N=76 Chronic Kidney Disease (CKD) Platelet Study
Chronic Kidney Diseases · Heart Attack · Stroke, Ischemic
Primary: ADP Induced Platelet Aggregation — 0; 6; 1 ohms — p=0.002
Phase 2 N=112 Ganaxolone in Posttraumatic Stress Disorder (PTSD)
PTSD
Primary: Change From Baseline in Clinician-Administered Posttrautamtic Stress Disorder (PTSD) Scale (CAPS) to Week 6 — 65.78; 62.67; 63.2; 61.30 Scores on a scale